Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production

New Brunswick, N.J., (Oct. 28, 2014) – Johnson & Johnson (NYSE: JNJ) has announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The company is closely collaborating with the World Health Organization (WHO), the National Institute of Allergy and Infectious Diseases (NIAID), as well as other key stakeholders, governments, and public health authorities on the clinical testing, development, production and distribution of the vaccine regimen. The